Does risperidone have a place in the treatment of nonschizophrenic patients?
There is a now a substantial body of evidence that suggests the new antipsychotic agent, risperidone, may be safe and effective for treating psychotic, affective or behavioural symptoms associated with various disorders other than schizophrenia, schizophreniform disorder or schizo-affective disorder. These conditions include bipolar disorder, obsessive-compulsive disorder, Tourette's syndrome, dementia, Lewy body disease, mental retardation, Parkinson's disease, idiopathic segmental dystonia and organic catatonia. Although much of the data is anecdotal or in the form of open studies, there is now emerging a small number of well controlled investigations supporting efficacy for mania, dementia, behavioural disturbance in mental retardation and conduct disorder. Conventional antipsychotics have long been used, either in a primary capacity or as an adjunct to treat these disorders; however, they have limited benefit, pose significant risks of extrapyramidal side-effects, and may cause the potentially life-threatening neuroleptic malignant syndrome. In contrast, risperidone at the recommended low doses may be efficacious and pose reduced risk of motor side-effects. This article reviews the evidence that risperidone may be an effective new treatment for disorders other than schizophrenia.
Schweitzer
I
I
Department of Psychiatry, University of Melbourne, Victoria, Australia. i.schweitzer@medicine.unimelb.edu.au
D001714:Bipolar Disorder / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003704:Dementia / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000209:etiology; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D016896:Treatment Outcome
D018967:Risperidone